Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CASR | P41180 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL354792 | 0.86 | HPGD (0.38) | NPC1RAB9ASMN1; SMN2ADRB2ADRB1 | |
| SCHEMBL10278013 | 0.85 | CASR (0.50) | SMN1; SMN2ADRB2ADRB1ALDH1A1S1PR1 | |
| SCHEMBL23654223 | 0.77 | ALDH1A1 (0.48) | NPC1ALDH1A1KMT2AMEN1S1PR1 | |
| SCHEMBL9051355 | 0.75 | IGF1R (0.50) | NPC1ALDH1A1KMT2AMEN1S1PR1 | |
| SCHEMBL10232031 | 0.74 | ESR1 (0.43) | ADRB2ADRB1KMT2AMEN1 | |
| SCHEMBL9053057 | 0.74 | S1PR2 (0.51) | NPC1ALDH1A1KMT2AMEN1S1PR1 | |
| SCHEMBL10278340 | 0.73 | SLC6A2 (0.40) | SMN1; SMN2ADRB2ADRB1KMT2AMEN1 | |
| SCHEMBL6010000 | 0.73 | CASR (0.42) | SMN1; SMN2ADRB2ADRB1ALDH1A1KMT2A | |
| SCHEMBL10278318 | 0.73 | GHSR (0.37) | ADRB2ADRB1CASR | |
| SCHEMBL10278319 | 0.73 | GRIA4 (0.43) | ADRB2ADRB1CA1CA2GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | NPC1 52/4885RAB9A 2815/4885SMN1; SMN2 58/4885 |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | NPC1 85/4885RAB9A 3030/4885SMN1; SMN2 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.